HomeCompareCSWC vs ZBH

CSWC vs ZBH: Dividend Comparison 2026

CSWC yields 9.56% · ZBH yields 1.08%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSWC wins by $11.1K in total portfolio value
10 years
CSWC
CSWC
● Live price
9.56%
Share price
$21.48
Annual div
$2.05
5Y div CAGR
-5.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$860.25
Full CSWC calculator →
ZBH
ZBH
● Live price
1.08%
Share price
$88.62
Annual div
$0.96
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$118.64
Full ZBH calculator →

Portfolio growth — CSWC vs ZBH

📍 CSWC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSWCZBH
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSWC + ZBH cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSWC pays
ZBH pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSWC
Annual income on $10K today (after 15% tax)
$812.72/yr
After 10yr DRIP, annual income (after tax)
$731.21/yr
ZBH
Annual income on $10K today (after 15% tax)
$92.08/yr
After 10yr DRIP, annual income (after tax)
$100.84/yr
At 15% tax rate, CSWC beats the other by $630.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSWC + ZBH for your $10,000?

CSWC: 50%ZBH: 50%
100% ZBH50/50100% CSWC
Portfolio after 10yr
$26.8K
Annual income
$489.45/yr
Blended yield
1.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ZBH right now

CSWC
Analyst Ratings
7
Buy
3
Hold
Consensus: Buy
Price Target
$22.17
+3.2% upside vs current
Range: $21.50 — $23.00
Altman Z
0.8
Piotroski
6/9
ZBH
Analyst Ratings
17
Buy
21
Hold
3
Sell
Consensus: Hold
Price Target
$105.60
+19.2% upside vs current
Range: $89.00 — $122.00
Altman Z
1.7
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSWC buys
0
ZBH buys
0
No recent congressional trades found for CSWC or ZBH in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSWCZBH
Forward yield9.56%1.08%
Annual dividend / share$2.05$0.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-5.6%0.2%
Portfolio after 10y$32.4K$21.2K
Annual income after 10y$860.25$118.64
Total dividends collected$9.2K$1.1K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusBuyHold
Analyst price target$22.17$105.60

Year-by-year: CSWC vs ZBH ($10,000, DRIP)

YearCSWC PortfolioCSWC Income/yrZBH PortfolioZBH Income/yrGap
1← crossover$11,603$902.60$10,809$108.54+$794.00CSWC
2$13,339$923.93$11,675$109.86+$1.7KCSWC
3$15,210$937.10$12,603$111.13+$2.6KCSWC
4$17,217$942.71$13,598$112.34+$3.6KCSWC
5$19,364$941.46$14,663$113.51+$4.7KCSWC
6$21,653$934.16$15,804$114.62+$5.8KCSWC
7$24,090$921.61$17,026$115.69+$7.1KCSWC
8$26,681$904.60$18,335$116.71+$8.3KCSWC
9$29,433$883.92$19,736$117.70+$9.7KCSWC
10$32,354$860.25$21,236$118.64+$11.1KCSWC

CSWC vs ZBH: Complete Analysis 2026

CSWCBDC

Capital Southwest Corporation is a business development company specializing in credit and private equity and venture capital investments in middle market companies, mezzanine, later stage, mature, late venture, emerging growth, buyouts, recapitalizations and growth capital investments. It does not invest in startups, publicly traded companies, real estate developments, project finance opportunities, oil and gas exploration businesses, troubled companies, turnarounds, and companies in which significant senior management is departing. In lower middle market, the firm typically invests in growth financing, bolt-on acquisitions, new platform acquisitions, refinancing, dividend recapitalizations, sponsor-led buyouts, and management buyouts situations. The investment structures are Unitranche debt, subordinated debt, senior debt, first and second lien debt, and preferred and common equity. The firm makes equity co-investments alongside debt investments, up to 20% of total check and only makes non-control investments. It prefers to invest in Industrial manufacturing and services, value-added distribution, healthcare products and services, business services, specialty chemicals, food and beverage, tech-enabled services and SaaS models. The firm seeks to invest in energy services and products, industrial technologies, and specialty chemicals and products. Within energy services and products, the firm seeks to invest in each segment of the industry, including upstream, midstream and downstream, excluding exploration and production with a focus on differentiated products and services, equipment and tool rental, consumable products, and drilling and completion chemicals. Within industrial technologies, it seeks to invest in automation and process controls, handling and packaging equipment, industrial filtration and fluid handling, measurement, monitoring and testing, professional tools, and sensors and instrumentation. Within and specialty chemicals and products, the firm seeks to invest in businesses that develop and manufacture highly differentiated chemicals and products including adhesives, coatings and sealants, catalysts and absorbents, cosmeceuticals, fine chemicals, flavors and fragrances, performance lubricants, polymers, plastics and composites, chemical dispensing and filtration equipment, professional and industrial trade consumables and tools, engineered solutions for HVAC, plumbing, and electrical installations, specified high performance materials for fire protection and oilfield applications. It may also invest in exceptional opportunities in building products. The firm seeks to invest in the United States. The firm seeks to make investments ranging from $5 to $25 million in securities. It seeks to make equity investments ranging from $5 million to $50 million and debt investments between $5 million and $20 million and co-invest in transaction size up to $40 million. It prefers to invest in companies with revenues approaching above $10 million, profitable operations, historical growth rate of at least 15 percent per year. Within the lower middle market, it seeks to invest in with less than $15 million in EBITDA and also opportunistically invests in the upper middle market, generally defined as companies with EBITDA in excess of $50 million. In addition to making direct investments, the firm allocates capital to syndicated first and second lien term loans in the upper middle market. Criteria for Upper Middle Market Syndicated 1st Lien is EBITDA Size more than $30 million, Closing Leverage greater than 4 times, investment hold size between $5 million and $7 million, investment yield greater than 6.5%. Criteria for Upper Middle Market Syndicated 2nd Lien is EBITDA Size more than $50 million, Closing Leverage greater than 6 times, investment hold size between $5 million and $7 million, investment yield greater than 9%. It prefers to take a majority and minority stake. The firm has the flexibility to hold investments for very long period in its portfolio companies. It may also invest through warrants. The firm prefers to take Board participation in its portfolio companies. Capital Southwest Corporation was founded on April 19, 1961 and is based in Dallas, Texas.

Full CSWC Calculator →

ZBHHealthcare

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Full ZBH Calculator →
📬

Get this CSWC vs ZBH comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSWC vs SCHDCSWC vs JEPICSWC vs OCSWC vs KOCSWC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.